The global estimated incidence of PMP is approximately 1 to 4 in one million annually. It appears to be more common in women, especially over the age of 50.
The patient, aged 51 years, was diagnosed with bilateral ovarian masses and underwent extensive surgical intervention including removal of the uterus, ovarian appendix and part of the omentum.
Subsequent testing revealed a high-grade mucinous tumor of the appendix with PMP, which required additional surgery.
The patient was found to have gelatinous deposits that remain in the abdomen, in the pelvis and around the cecum (first part of the colon) after surgery for an appendicular mucinous tumor.Due to the unique tendency of appendix cancer patients to spread to the abdominal lining (peritoneum), doctors at Apollo Cancer Center (ACC) resort to minimally invasive robotic cytoreductive surgery (CRS). The surgeon completely removed the remaining tumor from the stomach.
CRS is performed by "right hemicolectomy (removal of the colon including the appendix) to reduce the number of cancer cells in the abdominal cavity, a complete mesocolic excision (surgery to treat cancer arising from the colon and appendix) and peritonectomy and total Was done with omentectomy." Any possible microscopic residual tumor inside the abdomen can be eliminated with hyperthermy intraperitoneal chemotherapy (hot chemotherapy combined with chemo drugs),'' said Dr. Aji Pai, senior consultant, surgical oncology and robotic surgery at ACC O Thursday.
The robotic CRS approach is minimally invasive and minimizes pain, blood loss, scarring and discomfort.This also translates to faster recovery for the patient and a quicker return to normal life.
"After one year of follow-up, she is completely healthy and cancer-free," the doctor said.
“Robotic CRS offers a transformative approach that requires expertise in interventional and robotic techniques for precise tumor resection. “With reduced post-operative morbidity, minimal access and rapid recovery, this method is a viable option for patients whose cancer cells have spread to peritoneal surfaces in a limited manner and have implanted,” Dr. Ajit said.
He added, “We are thrilled by the successful clinical outcome and the potential of this approach to improve the lives of patients battling peritoneal cervical cancer, including ovarian, colonic and gastric cancer."
The patient, aged 51 years, was diagnosed with bilateral ovarian masses and underwent extensive surgical intervention including removal of the uterus, ovarian appendix and part of the omentum.
Subsequent testing revealed a high-grade mucinous tumor of the appendix with PMP, which required additional surgery.
The patient was found to have gelatinous deposits that remain in the abdomen, in the pelvis and around the cecum (first part of the colon) after surgery for an appendicular mucinous tumor.Due to the unique tendency of appendix cancer patients to spread to the abdominal lining (peritoneum), doctors at Apollo Cancer Center (ACC) resort to minimally invasive robotic cytoreductive surgery (CRS). The surgeon completely removed the remaining tumor from the stomach.
CRS is performed by "right hemicolectomy (removal of the colon including the appendix) to reduce the number of cancer cells in the abdominal cavity, a complete mesocolic excision (surgery to treat cancer arising from the colon and appendix) and peritonectomy and total Was done with omentectomy." Any possible microscopic residual tumor inside the abdomen can be eliminated with hyperthermy intraperitoneal chemotherapy (hot chemotherapy combined with chemo drugs),'' said Dr. Aji Pai, senior consultant, surgical oncology and robotic surgery at ACC O Thursday.
The robotic CRS approach is minimally invasive and minimizes pain, blood loss, scarring and discomfort.This also translates to faster recovery for the patient and a quicker return to normal life.
"After one year of follow-up, she is completely healthy and cancer-free," the doctor said.
“Robotic CRS offers a transformative approach that requires expertise in interventional and robotic techniques for precise tumor resection. “With reduced post-operative morbidity, minimal access and rapid recovery, this method is a viable option for patients whose cancer cells have spread to peritoneal surfaces in a limited manner and have implanted,” Dr. Ajit said.
He added, “We are thrilled by the successful clinical outcome and the potential of this approach to improve the lives of patients battling peritoneal cervical cancer, including ovarian, colonic and gastric cancer."
